<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04002323</url>
  </required_header>
  <id_info>
    <org_study_id>DOLAVI</org_study_id>
    <nct_id>NCT04002323</nct_id>
  </id_info>
  <brief_title>Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients</brief_title>
  <acronym>DOLAVI</acronym>
  <official_title>Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Virgen de las Nieves</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Virgen de las Nieves</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Thanks to the actual highly active antiretroviral therapy (HAART) patients living with HIV
      have a better life expectancy, becoming chronical patients. Today's antiretroviral treatment
      (ART) must be maintained for life to prevent disease progression until a cure is reached.
      Given this need, ARTs are becoming safer and more effective but are still toxic. Cause of
      that simplification therapies are real, reducing the number of different Antiretrovirals
      involved controlling the infection. This strategies include from monotherapy using/with
      protease inhibitors (PI), which was investigated with treatment-experienced patients and
      virologically suppressed, to dual therapies which recently were investigated in
      treatment-naïve and treatment-experienced patients with combinations such as dolutegravir
      (DTG) plus lamivudine (3TC), Dolutegravir plus rilpivirine or rilpivirine plus
      darunavir/ritonavir boosted.

      Nowadays dual therapy in real life (not into the context of a clinical trial) with
      dolutegravir plus lamivudine is largely studied in treatment-experienced patients who are
      virologically suppressed and got nearly a 100% efficacy results. Recently published results
      from clinical trials in treatment-naïve patients GEMINI 1 &amp;2, where efficacy of the dual
      therapy with DTG 50mg plus 3TC 300mg/QD was compared versus the efficacy of triple therapy
      with tenofovir disoproxil fumarate, emtricitabine and dolutegravir (TDF/FTC+ DTG) (QD). Both
      trials show similar efficacy results, with virologic suppression higher than 90% at week 48.

      Clinical trials are the gold standard to approve and add to the clinical practice new drugs
      and new therapies, but is also known that have some inconvenient like strict
      inclusion-exclusion criteria which put the study population far from being a real sample.
      Studies with real world data (RWD) have several strengths such as quality in medical
      attention and works like a bridge between clinical trials and standard clinical care,
      reducing/lowering general costs, improving results and accelerating the generation of
      knowledge.

      For all the reasons above, the primary objective of this study is to analyze in
      treatment-naïve HIV patients the effectiveness in real life of 3TC (300 mg p.o. q 24 h) plus
      DTG (50 mg p.o. q 24 h). Secondary objectives are: to describe the patient who receive this
      dual therapy, to quantify the time gap between the clinic visit and the first dose of dual
      therapy administrated evaluating this dual therapy as candidate to &quot;test and treat&quot;
      therapies; to analyze the viral load drop and the increase of cluster of differentiation 4
      (CD4) T lymphocytes levels; To analyze virological failures and previous mutations influence
      in basal resistance tests; and finally a pharmacoeconomic analysis, safety of the treatment
      and adherence to the healthcare system.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>48 Weeks</target_duration>
  <primary_outcome>
    <measure>Percentage of subjects with plasma HIV 1 RNA &lt;50 copies/milliliter at week 48</measure>
    <time_frame>48 weeks</time_frame>
    <description>The proportion of subjects with viral suppression (HIV-1 RNA &lt;50 copies/mL) among subjects who received at least one dose of study medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in lymphocytes cell counts at week 24 and 48</measure>
    <time_frame>Baseline, 24 weeks and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE)</measure>
    <time_frame>48 weeks</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation participant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinue Treatment</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">139</enrollment>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>HIV-1 ART-Naive</arm_group_label>
    <description>Lamivudine (300 mg p.o. q 24 h) plus Dolutegravir (50 mg p.o. q 24 h)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dolutegravir 50mg Tab</intervention_name>
    <description>The subjects starts their ART with this drugs, once a day</description>
    <arm_group_label>HIV-1 ART-Naive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine 300 mg</intervention_name>
    <description>The subjects starts their ART with this drugs, once a day</description>
    <arm_group_label>HIV-1 ART-Naive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study will be conducted in approximately 139 HIV-1 infected, ART-naive adults who began
        their ART with DTG 50mg plus 3TC 300mg , without limits of viral load or CD4 lymphocytes
        recount at screening.

        The following population will be assessed:

        Intent-to-treat (ITT) Population: This population will consist of all randomized subjects
        who receive at least one dose of study medication.

        Intent-to-treat modified (ITT-m) Population: this population will consist of subjects in
        the ITT Population with the exception of mild protocol violators, those who discontinue for
        reasons other than those related to treatment (such as adverse events, tolerability or lack
        of efficacy).

        Per protocol (PP) Population: This population will consist of subjects in the ITT
        Population with exception of major protocol violators, such as violations which could
        affect the assessment of antiviral activity.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV-1 infected adults (&lt;17 y.o.)

          2. Antiretroviral-naïve.

          3. Be able to comply with protocol requirements and instructions.

          4. Subject or the subject's representative capable of giving signed informed consent.

        Exclusion Criteria:

          1. Women who are breastfeeding or plan to become pregnant during the study.

          2. Patients who in the investigator's judgment, poses a significant drop out risk or life
             expectancy inferior to study ending.

          3. Patients with anticipated need to change the ART before study ending.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>CARMEN HIDALGO, Dr</last_name>
    <phone>+34 958 895 414</phone>
    <email>CHIDALGO72@GMAIL.COM</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SERGIO SEQUERA, Ph</last_name>
    <phone>+34 958 895 414</phone>
    <email>SERGIOSEQUERA@GMAIL.COM</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de Las Nieves</name>
      <address>
        <city>Granada</city>
        <state>Andalucía</state>
        <zip>18008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SERGIO SEQUERA, Ph</last_name>
      <phone>+34 958 895 414</phone>
      <email>SERGIOSEQUERA@GMAIL.COM</email>
    </contact>
    <investigator>
      <last_name>CARMEN HIDALGO, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>JUAN PASQUAU, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013 Nov 2;382(9903):1525-33. doi: 10.1016/S0140-6736(13)61809-7. Epub 2013 Oct 23. Review.</citation>
    <PMID>24152939</PMID>
  </reference>
  <reference>
    <citation>Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune Activation, Inflammation, and Non-AIDS Co-Morbidities in HIV-Infected Patients under Long-Term ART. Viruses. 2019 Feb 27;11(3). pii: E200. doi: 10.3390/v11030200. Review.</citation>
    <PMID>30818749</PMID>
  </reference>
  <reference>
    <citation>Pasquau J, Hidalgo-Tenorio C. Nuke-Sparing Regimens for the Long-Term Care of HIV Infection. AIDS Rev. 2015 Oct-Dec;17(4):220-30. Review.</citation>
    <PMID>26679853</PMID>
  </reference>
  <reference>
    <citation>Pasquau J, Hidalgo-Tenorio C, Montes ML, Romero-Palacios A, Vergas J, Sanjoaquín I, Hernández-Quero J, Aguirrebengoa K, Orihuela F, Imaz A, Ríos-Villegas MJ, Flores J, Fariñas MC, Vázquez P, Galindo MJ, García-Mercé I, Lozano F, de Los Santos I, de Jesus SE, García-Vallecillos C; QoLKAMON STUDY GROUP. High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial. PLoS One. 2018 Apr 12;13(4):e0195068. doi: 10.1371/journal.pone.0195068. eCollection 2018.</citation>
    <PMID>29649309</PMID>
  </reference>
  <reference>
    <citation>Taiwo BO, Zheng L, Stefanescu A, Nyaku A, Bezins B, Wallis CL, Godfrey C, Sax PE, Acosta E, Haas D, Smith KY, Sha B, Van Dam C, Gulick RM. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA &lt;500000 Copies/mL. Clin Infect Dis. 2018 May 17;66(11):1689-1697. doi: 10.1093/cid/cix1083.</citation>
    <PMID>29253097</PMID>
  </reference>
  <reference>
    <citation>Cahn P, Rolón MJ, Figueroa MI, Gun A, Patterson P, Sued O. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017 May 9;20(1):21678. doi: 10.7448/IAS.20.01.21678.</citation>
    <PMID>28537061</PMID>
  </reference>
  <reference>
    <citation>Palacios R, Mayorga M, González-Domenech CM, Hidalgo-Tenorio C, Gálvez C, Muñoz-Medina L, de la Torre J, Lozano A, Castaño M, Omar M, Santos J. Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study. J Int Assoc Provid AIDS Care. 2018 Jan-Dec;17:2325958218760847. doi: 10.1177/2325958218760847.</citation>
    <PMID>29529910</PMID>
  </reference>
  <reference>
    <citation>Pasquau J, de Jesus SE, Arazo P, Crusells MJ, Ríos MJ, Lozano F, de la Torre J, Galindo MJ, Carmena J, Santos J, Tornero C, Verdejo G, Samperiz G, Palacios Z, Hidalgo-Tenorio C; RIDAR Study Group. Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study). BMC Infect Dis. 2019 Feb 28;19(1):207. doi: 10.1186/s12879-019-3817-6.</citation>
    <PMID>30819101</PMID>
  </reference>
  <reference>
    <citation>Borghetti A, Lombardi F, Gagliardini R, Baldin G, Ciccullo A, Moschese D, Emiliozzi A, Belmonti S, Lamonica S, Montagnani F, Visconti E, De Luca A, Di Giambenedetto S. Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. BMC Infect Dis. 2019 Jan 17;19(1):59. doi: 10.1186/s12879-018-3666-8.</citation>
    <PMID>30654739</PMID>
  </reference>
  <reference>
    <citation>Baldin G, Ciccullo A, Borghetti A, Di Giambenedetto S. Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice. J Antimicrob Chemother. 2019 May 1;74(5):1461-1463. doi: 10.1093/jac/dkz009.</citation>
    <PMID>30726922</PMID>
  </reference>
  <reference>
    <citation>Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum in: Lancet. 2018 Nov 28;:.</citation>
    <PMID>30420123</PMID>
  </reference>
  <reference>
    <citation>Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, Madigan D, Makady A, Schneeweiss S, Tarricone R, Wang SV, Watkins J, Daniel Mullins C. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017 Sep;26(9):1033-1039. doi: 10.1002/pds.4297.</citation>
    <PMID>28913966</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>June 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2019</study_first_posted>
  <last_update_submitted>July 16, 2019</last_update_submitted>
  <last_update_submitted_qc>July 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Virgen de las Nieves</investigator_affiliation>
    <investigator_full_name>Carmen Hidalgo Tenorio</investigator_full_name>
    <investigator_title>SPECIALIST PHYSICIAN</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

